Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivia Rolfe

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinical & Experimental Ophthalmology|February 26, 2026
Australia's Rising Rates of Intravitreal Injections: Forecasting the Demand for Intravitreal Injections in Australia Using Data From the Pharmaceutical Benefits SchemeEmma Tovey Crutchfield, Olivia Rolfe, Elaine Chong
Clinical & Experimental Ophthalmology|November 20, 2025
The Burden of Treatment for Sporadic Unilateral Retinoblastoma in AustraliaOlivia Rolfe, James Elder, John McKenzie, et al.
Immunogenetics|June 1, 2019
Correction to: Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumabPeter A Johansson, Andrew Stark, Jane M Palmer, et al.
Immunogenetics|February 5, 2019
Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumabPeter A Johansson, Andrew Stark, Jane M Palmer, et al.
Retina (Philadelphia, Pa.)|August 16, 2024
HIGH-RISK HISTOPATHOLOGICAL FEATURES OF RETINOBLASTOMA FOLLOWING PRIMARY ENUCLEATION: A Global Study Of 1,426 Patients From 5 ContinentsSwathi Kaliki, Vijitha S Vempuluru, Komal Rajendra Bakal, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinical & Experimental Ophthalmology|February 26, 2026
Australia's Rising Rates of Intravitreal Injections: Forecasting the Demand for Intravitreal Injections in Australia Using Data From the Pharmaceutical Benefits SchemeEmma Tovey Crutchfield, Olivia Rolfe, Elaine Chong
Clinical & Experimental Ophthalmology|November 20, 2025
The Burden of Treatment for Sporadic Unilateral Retinoblastoma in AustraliaOlivia Rolfe, James Elder, John McKenzie, et al.
Immunogenetics|June 1, 2019
Correction to: Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumabPeter A Johansson, Andrew Stark, Jane M Palmer, et al.
Immunogenetics|February 5, 2019
Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumabPeter A Johansson, Andrew Stark, Jane M Palmer, et al.
Retina (Philadelphia, Pa.)|August 16, 2024
HIGH-RISK HISTOPATHOLOGICAL FEATURES OF RETINOBLASTOMA FOLLOWING PRIMARY ENUCLEATION: A Global Study Of 1,426 Patients From 5 ContinentsSwathi Kaliki, Vijitha S Vempuluru, Komal Rajendra Bakal, et al.
Pageof 1